Amryt Pharma (AMYT.L, AMYT LN)
Formed in 2015, Amryt Pharma acquires, develops and commercialises therapies for orphan (rare) diseases, diseases that have small rates of prevalence among country populations. Amryt is not involved in drug discovery but acquires its pipeline through the acquisition and in-licensing of orphan therapies. The company currently has four assets in its portfolio (AP101, AP102, AP103 and Lojuxta) that are targeting multiple orphan indications. These therapies span both development and commercial stages of the lifecycle. Amryt also reports modest revenues from Imlan, the company's derma-cosmetics range of products. Imlan is considered a non-core part of the company's portfolio.
|Athytrium Capital Mgmt||27.2|
|EdgePoint Investment Group||7.9|
|Highbridge Capital Mgmt||7.2|